-
Product Insights
Smoking Cessation – Drugs In Development, 2023
Global Markets Direct’s, ‘Smoking Cessation - Drugs In Development, 2023’, provides an overview of the Smoking Cessation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Smoking Cessation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Opium (Opioid) Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Opium (Opioid) Addiction - Drugs In Development, 2023’, provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ibogaine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ibogaine Drug Details Ibogaine is under development for the treatment of opioid use disorder....
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Noribogaine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Noribogaine Drug Details Noribogaine is under development for the treatment of anxiety, opioid use...
-
Product Insights
Opium (Opioid) Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Opium (Opioid) Addiction develops after using opioids regularly for a period. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). Its signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping, and pain in the bones. The predisposing factors include age, personal history/ family history of substance abuse, cigarette dependency, and psychological stress. The Opium...
-
Product Insights
Opium Withdrawal Syndrome Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Opium Withdrawal Syndrome Global Clinical Trials Review, H1, 2018" provides an overview of Opium Withdrawal Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Opium Withdrawal Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...